Metabolic-Redox Remodeling of Inflammatory Synovium by Mannose-Modified Selenium Nanoparticles for Osteoarthritis Therapy.

Authors

Yu-Qing Zou, Chen-Hao Xu, Bo-Wei Li, Leung Chan, Yi-Di Xu, Han-Bo Su, Rui Peng, Fang-Ji Luo, Ya-Chen Peng, Zhen-Yan Li, Vincent Kam Wai Wong, Xiao-Fei Zheng, Xing Ma, Zhen-Gang Zha, Tianfeng Chen, Huan-Tian Zhang

Published in

Advanced science (Weinheim, Baden-Wurttemberg, Germany). Pages e78188. Oct 06, 2026. Epub Oct 06, 2026.

Abstract

Osteoarthritis (OA) progression is driven by persistent synovial inflammation, amplified by oxidative stress and enhanced glycolysis. Our previous study has demonstrated that glucose transporter 1 (GLUT1) plays a key role in initiating OA synovitis via regulation of glycolysis. Single-cell RNA sequencing and tissue-specific fluorescent reporter mice (Prg4^GFPCreERt2 and Lyz2-iCre;tdTomato) reveal that GLUT1 marks a hyperinflammatory synovial state coupled to impaired selenoprotein-dependent redox homeostasis. Accordingly, mannose-modified selenium nanoparticles (M-SeNPs) are developed as an intra-articular nanotherapeutic targeting hypermetabolic synovial niches while restoring redox balance and reprogramming dysregulated metabolism. M-SeNPs are successfully synthesized and characterized, demonstrating preferential uptake by the GLUT1^high cells. Proteomic analysis indicates that the robust anti-inflammatory activity of M-SeNPs stems from coordinated metabolic reprogramming and reconstitution of the endogenous antioxidant system, driven by alterations in glycolytic protein and multiple selenoproteins. In vivo, studies demonstrate that, M-SeNPs selectively accumulate in inflamed synovial tissues, effectively alleviating OA-associated pain and restoring joint function. Histological and immunofluorescence analyses further demonstrate pronounced chondroprotection efficacy of M-SeNPs in OA mouse models, which is redominantly mediated by metabolic rewiring and redox homeostasis restoration in the GLUT1^high synoviocytes. Collectively, our results establish M-SeNPs as a compelling candidate for OA treatment via selective modulation of synovial metabolic pathway.

PMID:
42839644
Bibliographic data and abstract were imported from PubMed on 07 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.